A Global Perspective: PARP Inhibitors in the Treatment of Metastatic Breast Cancer

Get up to date with international insights on assessing and targeting BRCA1/2 and other DNA damage repair gene alterations in metastatic breast cancer with downloadable slides from a video roundtable plus an expert commentary.
Mark E. Robson, MD

ClinicalThought

Curious about what the latest with PARP inhibition in breast cancer? Read this commentary to gain expert perspectives on optimal current and future clinical use of PARP inhibitors in early, metastatic, and triple-negative breast cancer.

Mark E. Robson, MD Released: September 22, 2020
Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by an educational grant from
AstraZeneca

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue